Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs)

European Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2010, Pages 5919-5925

  Attolino, Emanuele ^a   Calderone, Vito ^b   Dragoni, Elisa ^a,b   Fragai, Marco ^b   Richichi, Barbara ^b   Luchinat, Claudio ^b   Nativi, Cristina ^b  

^a ProtEra Srl   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Inhibitors; Metalloproteinases; Structure based approach; Substituent effect; Sulfonamides

Indexed keywords

COLLAGENASE 3; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE;

ARTICLE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROPHILICITY; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION;

CRYSTALLOGRAPHY, X-RAY; MATRIX METALLOPROTEINASE 12; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NANOSTRUCTURES; PROTEASE INHIBITORS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; WATER;

EID: 78649319485     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.09.057     Document Type: Article

References (35)

1. E. Freire Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13 2008 869 874
2. S. Zucker, J. Cao, and W.T. Chen Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 2000 6642 6650
3. F. Mannello Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon Recent Patents Anti-Cancer Drug Discov. 1 2006 91 103
4. M. Pavlaki, and S. Zucker Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials Cancer Metastasis Rev. 22 2003 177 203
5. J.W. Skiles, N.C. Gonnella, and A.Y. Jeng The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors ChemMedChem 11 2004 2911 2977
6. B.G. Rao Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies Curr. Pharm. Des. 11 2005 295 322
7. E. Nuti, L. Panelli, F. Casalini, S.I. Avramova, E. Orlandini, S. Santamaria, S. Nencetti, T. Tuccinardi, A. Martinelli, G. Cercignani, N. D'Amelio, A. Maiocchi, F. Uggeri, and A. Rossello Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors J. Med. Chem. 52 2009 6347 6361
8. A. Agrawal, D. Romero-Perez, J.A. Jacobsen, F.J. Villarreal, and S.M. Cohen Zinc-binding groups modulate selective inhibition of MMPs ChemMedChem 3 2008 812 820
9. P. Janser, U. Neumann, W. Miltz, R. Felfel, and T. Buhl A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors Bioorg. Med. Chem. Lett. 16 2006 2632 2636
10. X.M. He, and D.C. Carter Atomic structure and chemistry of human serum albumin Nature 358 1992 209 215
11. L.M. Coussens, B. Fingleton, and L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392
12. L. Aureli, M. Gioia, I. Cerbara, S. Monaco, G.F. Fasciglione, S. Marini, P. Ascenzi, A. Topai, and M. Coletta Structural bases for substrate and inhibitor recognition by matrix metalloproteinases Curr. Med. Chem. 15 2008 2192 2222
13. C.M. Overall, and O. Kleifeld Towards third generation matrix metalloproteinase inhibitors for cancer therapy Br. J. Cancer 94 2006 941 946
14. T. Masuda, and Y. Nakayama Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty J. Med. Chem. 46 2003 3497 3501
15. M. Fragai, C. Nativi, B. Richichi, and C. Venturi Design in silico, synthesis and binding evaluation of a carbohydrate-based scaffold for structurally novel inhibitors of matrix metalloproteinases ChemBioChem 6 2005 1345 1349
16. V. Calderone, M. Fragai, C. Luchinat, C. Nativi, B. Richichi, and S. Roelens A high-affinity carbohydrate-containing inhibitor of matrix metalloproteinases ChemMedChem 1 2006 598 601
17. D.N. Meli, J.M. Loeffler, P. Baumann, U. Neumann, T. Buhl, D. Leppert, and S.L. Leib In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex J. Neuroimmunol. 151 2004 6 11
18. L. Devel, V. Rogakos, A. David, A. Makaritis, F. Beau, P. Cuniasse, A. Yiotakis, and V. Dive Development of selective inhibitors and substrate of matrix metalloproteinase-12 J. Biol. Chem. 281 2006 11152 11160
19. J. Lauer-Fields, K. Brew, J.K. Whitehead, S. Li, R.P. Hammer, and G.B. Fields Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors J. Am. Chem. Soc. 129 2007 10408 10417
20. L.G. Monovich, R.A. Tommasi, R.A. Fujimoto, V. Blancuzzi, K. Clark, W.D. Cornell, R. Doti, J. Doughty, J. Fang, D. Farley, J. Fitt, V. Ganu, R. Goldberg, R. Goldstein, S. Lavoie, R. Kulathila, W. Macchia, D.T. Parker, R. Melton, E. O'Byrne, G. Pastor, T. Pellas, E. Quadros, N. Reel, D.M. Roland, Y. Sakane, H. Singh, J. Skiles, J. Somers, K. Toscano, A. Wigg, S.Y. Zhou, L.J. Zhu, W.C. Shieh, S. Xue, and L.W. McQuire Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13 J. Med. Chem. 52 2009 3523 3538
21. L.J. MacPherson, E.K. Bayburt, M.P. Capparelli, B.J. Carroll, R. Goldstein, M.R. Justice, L. Zhu, S. Hu, R.A. Melton, L. Fryer, R.L. Goldberg, J.R. Doughty, S. Spirito, V. Blancuzzi, D. Wilson, E.M. O'Byrne, V. Ganu, and D.T. Parker Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits J. Med. Chem. 40 1997 2525 2532
22. A.Y. Jeng, M. Chou, and D.T. Parker Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase Bioorg. Med. Chem. Lett. 8 1998 897 902
23. R.P. Beckett, A.H. Davidson, A.H. Drummond, P. Huxley, and M. Whittaker Preclinical and clinical studies of MMP inhibitors in cancer Drug Discov. Today 1 1996 16 26
24. M. Whittaker, C.D. Floyd, P. Brown, and A.J. Gearing Design and therapeutic application of matrix metalloproteinase inhibitors Chem. Rev. 99 1999 2735 2776
25. I. Bertini, V. Calderone, M. Cosenza, M. Fragai, Y.-M. Lee, C. Luchinat, S. Mangani, B. Terni, and P. Turano Conformational variability of matrix metalloproteinases: beyond a single 3D structure Proc. Natl. Acad. Sci. U S A 102 2005 5334 5339
26. J.W. Skiles, N.C. Gonnella, and A.Y. Jeng The design, structure, and therapeutic application of matrix metalloproteinase inhibitors Curr. Med. Chem. 8 2001 425 474
27. A. Juengel, C. Ospelt, M. Thiel, M. Lesch, O. Schorr, B.A. Michel, R.E. Gay, C. Kolling, C. Flory, S. Gay, and M. Neidhart Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis Ann. Rheum. Dis. 69 2010 898 902
28. H. Takaishi, T. Kimura, S. Dalal, Y. Okada, and J. D'Armiento Joint diseases and matrix metalloproteinases: a role for MMP-13 Curr. Pharm. Biotechnol. 9 2008 47 54
29. R.E. Galardy, M.E. Cassabonne, C. Giese, J.H. Gilbert, F. Lapierre, H. Lopez, M.E. Schaefer, R. Stack, M. Sullivan, B. Summers, R. Tressler, D. Tyrrell, J. Wee, S.D. Allen, J.J. Castellot, J.P. Barletta, G.S. Schultz, L.A. Fernandez, S. Fisher, T.Y. Cui, H.G. Foellmer, D. Grobelny, and W.M. Holleran Inhibition of matrix metalloproteinases: therapeutic Potential Ann. New York Acad. Sci. V 732 1994 315 323
30. S.J. Giebel, G. Menicucci, and P.G. McGuire Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier A Das. Lab. Invest. 85 2005 597 607
31. K. Ohno-Matsui, T. Uetama, T. Yoshida, M. Hayano, T. Itoh, I. Morita, and M. Mochizuki Reduced retinal angiogenesis in MMP-2-deficient mice Investigative Ophthalmology & Visual Science 44 2003 5370 5375
32. Y. Adachi, H. Yamamoto, F. Itoh, Y. Hinoda, Y. Okada, and K. Imai Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers Gut 45 1999 252 258
33. W. Hornebeck Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival Pathol. Biol. 51 2003 569 573
34. I. Bertini, V. Calderone, M. Fragai, A. Giachetti, M. Loconte, C. Luchinat, M. Maletta, C. Nativi, and K.J. Yeo Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases J. Am. Chem. Soc. 129 2007 2466 2475
35. F.J. Moy, P.K. Chanda, J. Chen, S. Cosmi, W. Edris, J.I. Levin, T.S. Rush, J. Wilhelm, and R. Powers Impact of mobility on structure-based drug design for the MMPs J. Am. Chem. Soc. 124 2002 12658 12659